A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Indatuximab ravtansine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Biotest Pharmaceuticals
- 30 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 17 Jul 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.